Last edition
News about "Roche"
The US Food and Drug Administration reviews concerns over Ocrevus, as safety and efficacy questions emerge for its use in primary progressive multiple sclerosis patients.
Roche | 16/04/2026 | By News Bureau
Roche Secures CE Mark for Blood-Based Test to Monitor Multiple Sclerosis
Roche’s Elecsys NfL test receives CE approval, offering a simple blood-based method to detect neuroinflammation in multiple sclerosis, improving monitoring access and supporting more timely, personalised disease management.
Roche | 14/04/2026 | By News Bureau
Chugai Announces Discontinuation of Emugrobart Trials in SMA and FSHD
Roche halts development after mid-stage trials fail to show consistent functional benefits, while obesity-focused trials continue amid promising scientific rationale.
Roche | 25/03/2026 | By News Bureau | 120
Roche Boosts AI Muscle with Nvidia Chip Expansion to Accelerate Drug Discovery
Swiss pharma major Roche has significantly expanded its artificial intelligence (AI) capabilities by deploying thousands of advanced GPUs from Nvidia, marking one of the largest AI infrastructure investments in the pharmaceutical sector.
Roche | 17/03/2026 | By Darshana
Roche Reports Update on PERSEVERA Breast Cancer Trial
Roche reported that the Phase III persevERA study in ER-positive advanced breast cancer did not meet its primary endpoint, though giredestrant plus palbociclib showed numerical improvement and a tolerable safety profile.
Roche | 09/03/2026 | By News Bureau
Roche's Fenebrutinib Shows Promise in Third Phase III MS Trial
Roche reported positive Phase III FENhance 1 results, with fenebrutinib reducing relapses by 51 percent in relapsing multiple sclerosis, consistent with prior FENhance 2 and FENtrepid data. The company plans regulatory submissions, positioning fenebrutinib as a potential first-in-class BTK inhibitor for relapsing and primary progressive MS.
Roche | 02/03/2026 | By News Bureau | 136
Roche's Fenebrutinib Matches Ocrevus in Slowing Disability Progression in PPMS Phase III Trial
Phase III FENtrepid study shows oral BTK inhibitor fenebrutinib achieved non-inferiority to Ocrevus in primary progressive multiple sclerosis, reducing disability progression risk by 12 percent with consistent subgroup benefit.
Roche | 10/02/2026 | By News Bureau | 148
Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.
Roche | 09/02/2026 | By News Bureau | 131
US FDA Approves Roche's Lunsumio VELO for Subcutaneous Use in Follicular Lymphoma
The US FDA has approved Roche’s Lunsumio VELO for subcutaneous use in Relapsed or Refractory Follicular Lymphoma, cutting administration time to about one minute and supported by strong complete response data in later-line patients.
Roche | 22/12/2025 | By News Bureau | 155
Takeda Becomes a BaseLaunch Partner
BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.
Roche | 19/12/2025 | By News Bureau | 100
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy